Therapeutic targeting of IL-1 signaling further supports the pathological role of IL-1 in AD, with the administration of IL-1 receptor-blocking antibodies significantly reducing neuroinflammation and improving cognitive function in AD models [242]. The gene discussed is IL1A; the disease is Alzheimer disease.